Literature DB >> 23271353

The tumor microenvironment in follicular lymphoma.

Zhi-Zhang Yang1, Stephen M Ansell.   

Abstract

Like other B-cell lymphomas, the development and progression of follicular lymphoma (FL) involves complex interactions between the neoplastic B cells and the surrounding microenvironment. Malignant B cells can manipulate the microenvironment by skewing the differentiation of immune cells, attracting regulatory T cells or suppressive monocytes, or secreting cytokines that promote an immunosuppressive environment. The importance of the microenvironment in FL has been demonstrated using methodologies such as gene expression profiling, which has shown that the nature of the tumor microenvironment predicts survival in patients with FL and may influence the response to immunotherapy and risk of transformation. Strategies that both enhance an effective antitumor response and reverse immunosuppression and dysfunction will be essential in the development of effective immunotherapeutic approaches in this disease.

Entities:  

Mesh:

Year:  2012        PMID: 23271353

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  14 in total

1.  Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.

Authors:  Megan M Herr; Sara J Schonfeld; Graça M Dores; Diana R Withrow; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

Review 2.  T cells in tumor microenvironment.

Authors:  Yağmur Kiraz; Yusuf Baran; Ayten Nalbant
Journal:  Tumour Biol       Date:  2015-10-18

3.  Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

Authors:  Jason R Westin; Fuliang Chu; Min Zhang; Luis E Fayad; Larry W Kwak; Nathan Fowler; Jorge Romaguera; Fredrick Hagemeister; Michelle Fanale; Felipe Samaniego; Lei Feng; Veerabhadran Baladandayuthapani; Zhiqiang Wang; Wencai Ma; Yanli Gao; Michael Wallace; Luis M Vence; Laszlo Radvanyi; Tariq Muzzafar; Rinat Rotem-Yehudar; R Eric Davis; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2013-12-11       Impact factor: 41.316

4.  Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release.

Authors:  Pooja Sabhachandani; Saheli Sarkar; Seamus Mckenney; Dashnamoorthy Ravi; Andrew M Evens; Tania Konry
Journal:  J Control Release       Date:  2018-12-12       Impact factor: 9.776

5.  Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.

Authors:  Jacob P Smeltzer; Jason M Jones; Steven C Ziesmer; Deanna M Grote; Bing Xiu; Kay M Ristow; Zhi Zhang Yang; Grzegorz S Nowakowski; Andrew L Feldman; James R Cerhan; Anne J Novak; Stephen M Ansell
Journal:  Clin Cancer Res       Date:  2014-04-11       Impact factor: 12.531

6.  An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.

Authors:  Suresh Veeramani; Sue E Blackwell; William H Thiel; Zhi-Zhang Yang; Stephen M Ansell; Paloma H Giangrande; George J Weiner
Journal:  Cancer Immunol Res       Date:  2019-08-05       Impact factor: 11.151

7.  Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.

Authors:  Hsiling Chiu; Preeti Trisal; Chad Bjorklund; Soraya Carrancio; Estela G Toraño; Carla Guarinos; Despoina Papazoglou; Patrick R Hagner; Asma Beldi-Ferchiou; Karin Tarte; Marie-Hélène Delfau-Larue; Franck Morschhauser; Alan G Ramsay; Anita K Gandhi
Journal:  Br J Haematol       Date:  2019-02-14       Impact factor: 6.998

8.  Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphoma.

Authors:  Hongyan Wu; Xinyi Tang; Hyo Jin Kim; Shahrzad Jalali; Joshua C Pritchett; Jose C Villasboas; Anne J Novak; Zhi-Zhang Yang; Stephen M Ansell
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

9.  IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma.

Authors:  B Xiu; Y Lin; D M Grote; S C Ziesmer; M P Gustafson; M L Maas; Z Zhang; A B Dietz; L F Porrata; A J Novak; A-B Liang; Z-Z Yang; S M Ansell
Journal:  Blood Cancer J       Date:  2015-07-31       Impact factor: 11.037

10.  Follicular B Cell Lymphoma with Accompanying Ischemic Gastritis Completely Resolved by Rituximab.

Authors:  Anam Tariq; Neal Mehta; Kathryn Peroutka
Journal:  Am J Case Rep       Date:  2017-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.